Despite extraordinary efforts to profile cancer genomes, interpreting the vast amount of genomic data in the light of cancer evolution remains challenging. Here we demonstrate that neutral tumor evolution results in a power-law distribution of the mutant allele frequencies reported by next-generation sequencing of tumor bulk samples. We find that the neutral power law fits with high precision 323 of 904 cancers from 14 types and from different cohorts. In malignancies identified as evolving neutrally, all clonal selection seemingly occurred before the onset of cancer growth and not in later-arising subclones, resulting in numerous passenger mutations that are responsible for intratumoral heterogeneity. Reanalyzing cancer sequencing data wit...
Tumours accumulate many somatic mutations in their lifetime. Some of these mutations, drivers, conve...
Abstract Analysis of spatial and temporal genetic heterogeneity in human cancers has revealed that s...
Sequencing studies of breast tumor cohorts have identified many prevalent mutations, but provide lim...
Next-generation sequencing data from human cancers are often difficult to interpret within the conte...
The cancer genome is shaped by three components of the evolutionary process: mutation, selection and...
Recently available cancer sequencing data have revealed a complex view of the cancer genome containi...
A.S. is supported by The Chris Rokos Fellowship in Evolution and Cancer. B.W. is supported by the G...
Subclonal architectures are prevalent across cancer types. However, the temporal evolutionary dynami...
Given the implications of tumor dynamics for precision medicine, there is a need to systematically c...
Accelerating technological advances have allowed the widespread genomic profiling of tumors. As yet,...
Background: All cancer arise as a result of a somatic mutation, several models have been developed t...
Advanced colorectal cancer harbors extensive intratumor heterogeneity shaped by neutral evolution; h...
Abstract Background Detailed modelling of the neutral mutational process in cancer cells is crucial ...
We develop a branching process with accumulating mutations to model neutral tumor evolution. Further...
Background: The large-scale availability of whole-genome sequencing profiles from bulk DNA sequencin...
Tumours accumulate many somatic mutations in their lifetime. Some of these mutations, drivers, conve...
Abstract Analysis of spatial and temporal genetic heterogeneity in human cancers has revealed that s...
Sequencing studies of breast tumor cohorts have identified many prevalent mutations, but provide lim...
Next-generation sequencing data from human cancers are often difficult to interpret within the conte...
The cancer genome is shaped by three components of the evolutionary process: mutation, selection and...
Recently available cancer sequencing data have revealed a complex view of the cancer genome containi...
A.S. is supported by The Chris Rokos Fellowship in Evolution and Cancer. B.W. is supported by the G...
Subclonal architectures are prevalent across cancer types. However, the temporal evolutionary dynami...
Given the implications of tumor dynamics for precision medicine, there is a need to systematically c...
Accelerating technological advances have allowed the widespread genomic profiling of tumors. As yet,...
Background: All cancer arise as a result of a somatic mutation, several models have been developed t...
Advanced colorectal cancer harbors extensive intratumor heterogeneity shaped by neutral evolution; h...
Abstract Background Detailed modelling of the neutral mutational process in cancer cells is crucial ...
We develop a branching process with accumulating mutations to model neutral tumor evolution. Further...
Background: The large-scale availability of whole-genome sequencing profiles from bulk DNA sequencin...
Tumours accumulate many somatic mutations in their lifetime. Some of these mutations, drivers, conve...
Abstract Analysis of spatial and temporal genetic heterogeneity in human cancers has revealed that s...
Sequencing studies of breast tumor cohorts have identified many prevalent mutations, but provide lim...